In a Move that May Get Significant Pushback, Lilly Signals that it Can Recoup 340B Underpayments from Entities at its Discretion

Eli Lilly signaled late last week that it thinks it can seek more for its products from 340B covered entities if it learns later that it charged them less than what the company perceives the law allows.

Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than what the company perceives the 340B statute

Read More »

Hospital Groups Pan GSK’s New 340B Contract Pharmacy Policy, PhRMA Says It Will Continue to Push for Reform

Hospital groups are criticizing GlaxoSmithKline's new 340B contract pharmacy policy. PhRMA says it will keep pushing to change 340B.

America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to

Read More »

News Alert: GlaxoSmithKline Becomes the 14th Drug Maker to Limit 340B Contract Pharmacies

GlaxoSmithKline today announced a new 340B contract pharmacy policy that affects nine of its inhaled medicines and applies to hospitals only.

UPDATE Monday, Feb. 14, 2022, 1:30 p.m. EST—The U.S. Health Resources and Services Administration (HRSA) said, “We are reviewing GSK’s policy and will evaluate next steps as needed.”

Drug manufacturer GlaxoSmithKline (GSK) told 340B covered entities this morning that effective

Read More »

News Alert: Biden Praises Congresswoman’s “Relentless” Work on 340B During Major Speech on Drug Pricing Reform

During a major speech today on drug pricing reform, President Biden applauded U.S. Rep. Abigail Spanberger (D-Va.) for her “relentless” work to ensure that the 340B statute “is actually enforced.”

President Joe Biden today during a major speech on drug pricing reform applauded U.S. Rep. Abigail Spanberger (D-Va.) for being “relentless in making sure” that the 340B statute “is actually enforced.”

Biden and U.S. Health and Human Services (HHS) Secretary

Read More »

Exclusive: AIDS Healthcare Foundation Says Re-Opening 340B Law Over Contract Pharmacy Fight Will Backfire

An AIDS Healthcare Foundation activist handed out Let it B signs supporting the 340B program during a September 2021 protest in front of U.S. Rep. Scott Peters' (D-Calif.) district office in San Diego.

AIDS Healthcare Foundation (AHF) today criticized efforts to introduce federal legislation to address drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies. It said the drug industry “will certainly use any legislation as an opportunity to further

Read More »

Biden and Becerra Slated to Speak at NACHC Event Next Week

President Joe Biden (left) and HHS Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ (NACHC) Policy and Issues Virtual Forum.

President Joe Biden and U.S. Health and Human Services (HHS) Secretary Xavier Becerra are scheduled to speak on Monday, Feb. 14, during the National Association of Community Health Centers’ Policy and Issues Virtual Forum, NACHC announced on Tuesday.

Securing Biden

Read More »

GSK Providing Refunds for 340B Overcharges During Q1 2020

GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

Drug manufacturer GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

GSK posted a public notice about the repayments on the U.S. Health Resources and Services Administration web site this

Read More »

HRSA Says at Least Three Hospitals Have Lost 340B Eligibility So Far Due to COVID-19 Patient Mix Changes

St. Elizabeth Healthcare in Ft. Thomas, Ky., is one of three hospitals known to have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. More are expected to lose eligibility soon.

The U.S. Health Resources and Services Administration (HRSA) said yesterday it knows of three hospitals that have withdrawn from the 340B program because changes in patient mix linked to the COVID-19 pandemic caused them to lose their eligibility. There could

Read More »

Democratic Senator’s Illness Stalls Action on Drug Pricing Indefinitely

Sen. Ben Ray Lujan's (D-N.M.) recent stroke and absence makes it even less likely that Congress will pass Democratic drug pricing legislation any time soon.

Prospects for passage of Democratic drug pricing legislation as part of the Build Back Better (BBB) Act dimmed again last week with news that Sen. Ben Ray Lujan (D-N.M.) had a stroke on Jan 27.

Lujan’s chief of staff

Read More »

Second Major 340B Stakeholder Says Congress May Need to Stop Drug Makers’ Contract Pharmacy Actions

NACHC is the second major 340B covered entity group in recent days to say publicly that Congress might need to resolve the impasse over 340B contract pharmacy.

The National Association of Community Health Centers (NACHC) told Republican members of Congress last week that “congressional action may be the only solution” to drug makers’ “aggressive actions to limit patients’ access to affordable medications at contract pharmacies.”

NACHC’s

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live